Overall, our findings demonstrate that the co-occurrence of TIGIT and CD155 in PDAC tumor microenvironment weakens the favorable outcomes for PDAC patients regardless of whether treated with ACT or not (1 vs 2; 3 vs 4), highlighting the need for subgroup analysis strategies to stratify patients for more rational and effective treatments. This evidence concerns the gene TIGIT and neoplasm.